• 1
    Ligtenberg G, Hene RJ, Blankestijn PJ, Koomans HA. Cardiovascular risk factors in renal transplant patients: cyclosporin A versus tacrolimus. J Am Soc Nephrol 2001; 12: 368373.
  • 2
    Woo YM, Jardine AG, Clark AF et al. Early graft function and patient survival following cadaveric renal transplantation. Kidney Int 1999; 55: 692699.
  • 3
    Dimeny E, Wahlberg J, Lithell H, Fellstrom B. Hyperlipidaemia in renal transplantation – risk factor for long-term graft outcome. Eur J Clin Invest 1995; 25: 574583.
  • 4
    Peschke B, Scheuermann EH, Geiger H, Bolscher S, Kachel HG, Lenz T. Hypertension is associated with hyperlipidemia, coronary heart disease and chronic graft failure in kidney transplant recipients. Clin Nephrol 1999; 51: 290295.
  • 5
    Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63: 977983.
  • 6
    Mayer A. Chronic rejection and graft half-life: five-year follow-up of the European tacrolimus multicenter renal study. Transplant Proc 2002; 34: 1491.
  • 7
    Moons P, De Geest S, Versteven K et al. Psychometric properties of the ‘Modified Transplant Symptom Occurrence and Symptom Distress Scale’. J Nurs Meas 2001; 9: 115134.
  • 8
    Artz MA, Boots JM, Ligtenberg G et al. Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus. J Am Soc Nephrol 2003; 14: 18801888.
  • 9
    The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2002; 25 (Suppl. 1): S5S20.
  • 10
    Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 18371847.
  • 11
    Sermeus W, Delesie L. Ridit analysis on ordinal data. West J Nurs Res 1996; 18: 351359.
  • 12
    Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605612.
  • 13
    Gjertson DW, Cecka JM, Terasaki PI. The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival. Transplantation 1995; 60: 13841388.
  • 14
    Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 2002; 73: 775782.
  • 15
    Hariharan S, McBride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62: 311318.
  • 16
    Hariharan S. Long-term kidney transplant survival. Am J Kidney Dis 2001; 38 (Suppl. 6): S44S50.
  • 17
    Pichler RH, Franceschini N, Young BA et al. Pathogenesis of cyclosporine nephropathy: roles of angiotensin II and osteopontin. J Am Soc Nephrol 1995; 6: 11861196.
  • 18
    Shihab FS, Andoh TF, Tanner AM et al. Role of transforming growth factor-beta 1 in experimental chronic cyclosporine nephropathy. Kidney Int 1996; 49: 11411151.
  • 19
    Shihab FS, Bennett WM, Tanner AM, Andoh TF. Mechanism of fibrosis in experimental tacrolimus nephrotoxicity. Transplantation 1997; 64: 18291837.
  • 20
    Mohamed MA, Robertson H, Booth TA, Balupuri S, Kirby JA, Talbot D. TGF-beta expression in renal transplant biopsies: a comparative study between cyclosporin-A and tacrolimus. Transplantation 2000; 69: 10021005.
  • 21
    Bicknell GR, Williams ST, Shaw JA, Pringle JH, Furness PN, Nicholson ML. Differential effects of cyclosporin and tacrolimus on the expression of fibrosis-associated genes in isolated glomeruli from renal transplants. Br J Surg 2000; 87: 15691575.
  • 22
    Carvalho MF, Soares V. Hyperlipidemia as a risk factor of renal allograft function impairment. Clin Transplant 2001; 15: 4852.
  • 23
    Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 1998; 53: 217222.
  • 24
    Ponticelli C. Progression of renal damage in chronic rejection. Kidney Int 2000; 57 (Suppl. 75): S62S70.
  • 25
    Oellerich M, Armstrong VW, Schutz E, Shaw LM. Therapeutic drug monitoring of cyclosporine and tacrolimus. Update on Lake Louise Consensus Conference on cyclosporin and tacrolimus. Clin Biochem 1998; 31: 309316.
  • 26
    Mahalati K, Belitsky P, Sketris I, West K, Panek R. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 1999; 68: 5562.
  • 27
    Levy GA. C2 monitoring strategy for optimising cyclosporin immunosuppression from the Neoral formulation. BioDrugs 2001; 15: 279290.
  • 28
    Cole E, Maham N, Cardella C et al. Clinical benefits of neoral C2 monitoring in the long-term management of renal transplant recipients. Transplantation 2003; 75: 20862090.
  • 29
    Ogden LG, He J, Lydick E, Whelton PK. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension 2000; 35: 539543.
  • 30
    Weir MR, Fink JC. Risk for posttransplant Diabetes mellitus with current immunosuppressive medications. Am J Kidney Dis 1999; 34: 113.
  • 31
    Van Duijnhoven EM, Christiaans MHL, Boots JMM, Nieman FHM, Wolffenbuttel BHR, Van Hooff JP. Glucose metabolism in the first 3 years after renal transplantation in patients receiving tacrolimus versus cyclosporine-based immunosuppression. J Am Soc Nephrol 2002; 13: 213220.
  • 32
    Duijnhoven EM, Boots JM, Christiaans MH, Wolffenbuttel BH, Van Hooff JP. Influence of tacrolimus on glucose metabolism before and after renal transplantation: a prospective study. J Am Soc Nephrol 2001; 12: 583588.
  • 33
    Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000; 11: 17351743.
  • 34
    Testa MA, Simonson DC. Assesment of quality-of-life outcomes. N Engl J Med 1996; 334: 835840.
  • 35
    Leventhal H, Diefenbach M, Leventhal EA. Illness cognition: using common sense to understand treatment adherence and affect cognition interactions. Cogn Ther Res 1992; 16: 143163.
  • 36
    Didlake RH, Dreyfus K, Kerman RH, Van Buren CT, Kahan BD. Patient noncompliance: a major cause of late graft failure in cyclosporine-treated renal transplants. Transplant Proc 1988; 20 (Suppl. 3): S63S69.
  • 37
    De Geest S, Borgermans L, Gemoets H et al. Incidence, determinants, and consequences of subclinical noncompliance with immunosuppressive therapy in renal transplant recipients. Transplantation 1995; 59: 340347.